Meeting
2018 Genitourinary Cancers Symposium
A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
Authors
Robert J. Motzer
Memorial Sloan Kettering Cancer Center, New York, NY
Robert J. Motzer , Viktor Grünwald , Thomas E. Hutson , Camillo Porta , Thomas Powles , Masatoshi Eto , Corina E. Dutcus , Mahadi Ali Baig , Lea Dutta , Di Li , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02811861
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS706)
DOI
10.1200/JCO.2018.36.6_suppl.TPS706
Abstract #
TPS706
Poster Bd #
L13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).
First Author: Robert J. Motzer
Poster
2019 ASCO Annual Meeting
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
First Author: Vicky Makker
Poster
2017 ASCO Annual Meeting
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC).
First Author: Brian I. Rini
Poster
2014 ASCO Annual Meeting
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.
First Author: Richard S. Finn